BB's Stock Haven

[Mingy]

TPHM = SCAM, read this. Whats going on now is nothing more than manipulation by the insiders and broker dealers to try to create hype for the stock. You watch, short time from now we will be well below these prices. This company is a total scam

From the companies 10q I First I want to point out that Thomas Pharmaceuticals used to be owned by Ivoice. So why does Thomas borrow so much money from Ivoice you ask? Well its simple, IVOICE converts the debt issued to it by Thomas, into common stock, and then dumps it on the market. This is nothing more than a scam, avoid this like the plague. These are just some of the many red flags of fraud and deception by the company.

From 10Q,
iVoice may, at its discretion, convert the outstanding principal and accrued interest, in whole or in part, into a number of shares of Thomas Pharmaceuticals Class A Common Stock at the price per share equal to eighty percent (80%) of the lowest closing bid price of the Common Stock for the five (5) trading days immediately preceding the conversion date.

From 10Q, history of debt issued to ivoice, from Thomas.

On January 6, 2006 the Company issued to iVoice a $360,000 secured convertible debenture due on January 1, 2013 bearing interest of 10%, compounded quarterly. During the nine months ended September 30, 2009, the Company issued 54,000,000 shares of Class A common stock as repayment of principal of $4,320. As of September 30, 2009 the remaining principal balance of the convertible debenture was $343,312 plus $158,774 of accrued interest.

On January 6, 2006 the Company issued to iVoice a $100,000 administrative service convertible debenture due on January 1, 2013 bearing interest of 10%, compounded quarterly. This debenture is issued in lieu of payments on the Administrative Services Agreement of the same date. As of September 30, 2009 the remaining principal balance of the convertible debenture was $100,000 plus $44,594 of accrued interest.

On April 27, 2006 the Company issued to iVoice a $225,000 secured convertible debenture due on January 1, 2013 bearing interest of 10%, compounded quarterly. As of September 30, 2009 the remaining principal balance of the convertible debenture was $225,000 plus $90,725 of accrued interest.

On February 7, 2007, the Company issued to iVoice a $25,000 secured convertible debenture due on February 6, 2014 bearing interest of 10%, compounded quarterly. As of September 30, 2009 the remaining principal balance of the convertible debenture was $25,000 plus $7,452 of accrued interest.

http://www.sec.gov/Archives/edgar/data/1391428/000118518509001213/thomaspharma10q093009.htm